News & Announcements
TECHNICAL.LY BALTIMORE: PARAGON PICKS UP MORE MD. MANUFACTURING SPACE IN $18M DEAL WITH NOVAVAX
June 27, 2019
Along with assuming control of the biotech facilities in Gaithersburg, more than 100 Novavax employees will join the Baltimore-based gene therapy unit.
Baltimore’s Paragon is adding more space for biotech manufacturing in Maryland.
Through a partnership with Paragon Gene Therapy parent Catalent Biologics, the gene therapy-focused unit is assuming two clinical development and manufacturing sites currently operated by Gaithersburg-based vaccine developer Novavax and acquiring manufacturing equipment for $18 million in cash, the companies announced on Thursday.
Read the full story at Technical.ly Baltimore.